MediWound’s flagship innovative drug, NexoBrid™, is indicated for the removal of eschar in adults with deep partial- and full-thickness thermal burns, a process also known as debridement.
NexoBrid™ contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelain”, which is extracted from the stem of the pineapple plant. It was studied by more than 100 leading burn specialists worldwide in 7 clinical studies involving more than 550 patients.
NexoBrid™ removes the eschar without harming viable tissue, in the majority of cases, after only a single 4-hour topical application at the patients’ bedside. This early, non-surgical, successful eschar removal, allows the physician to diagnose the burn depth simply by direct visual assessment of the debrided clean wound bed and reach an informed decision on further treatment. Furthermore, NexoBrid™’s effective eschar removal significantly reduces the extent of surgery required, without compromising surrounding healthy tissues.
In December 2012, NexoBrid™ received a European Marketing Authorization*. Additional multinational studies commenced recently.
*In the US, NexoBrid™ is an investigational drug product.